A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NBIX SEC filings page.
Neurocrine Biosciences Inc (NBIX) reported $2.9B in revenue for fiscal year 2025, up 21.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth is increasingly funding research while operating leverage converts scale into cash, despite a FY2025 operating-margin step-down.
From FY2023 to FY2025, revenue increased51.6% while operating income increased146.8% , showing that added scale reached operations faster than sales. By FY2025, free cash flow margin reached26.2% while R&D consumed35.5% of revenue, so cash generation coexists with unusually heavy reinvestment.
Operating cash flow was
Liabilities were
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Neurocrine Biosciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Neurocrine Biosciences Inc scores 78/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Neurocrine Biosciences Inc scores 84/100 on it among other operating companies.
Neurocrine Biosciences Inc carried $0.42 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2025. With no long-term debt figure for fiscal year 2025, Neurocrine Biosciences Inc is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 64/100 among other operating companies.
Neurocrine Biosciences Inc held $3.39 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 3.39. Liquidity ranks operating companies on that ratio, and Neurocrine Biosciences Inc scores 83/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Neurocrine Biosciences Inc scores 90/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Neurocrine Biosciences Inc scores 77/100 on it among other operating companies.
Neurocrine Biosciences Inc scores 9.03, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $16.9B against total liabilities of $1.4B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Neurocrine Biosciences Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Neurocrine Biosciences Inc generates $1.64 in operating cash flow ($782.7M OCF vs $478.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Neurocrine Biosciences Inc generated $1.1B in revenue in Q3 2026. This represents an increase of 41.2% from the same quarter a year earlier. Against the prior quarter it is up 17.1%.
Neurocrine Biosciences Inc's EBITDA was $375.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.1% from the same quarter a year earlier. Against the prior quarter it is up 112.9%.
Neurocrine Biosciences Inc reported $206.5M in net income in Q3 2026. This represents a decrease of 1.4% from the same quarter a year earlier. Against the prior quarter it is up 43.0%.
Neurocrine Biosciences Inc earned $1.96 per diluted share (EPS) in Q3 2026. This represents a decrease of 3.9% from the same quarter a year earlier. Against the prior quarter it is up 41.0%.
Cash & Balance Sheet
Neurocrine Biosciences Inc generated $383.6M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 79.0% from the same quarter a year earlier. Against the prior quarter it is up 198.3%.
Neurocrine Biosciences Inc held $641.5M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Neurocrine Biosciences Inc's gross margin was 97.6% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 0.6 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.
Neurocrine Biosciences Inc's operating margin was 29.5% in Q3 2026, reflecting core business profitability. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.7 percentage points.
Neurocrine Biosciences Inc's net profit margin was 18.4% in Q3 2026, showing the share of revenue converted to profit. This is down 8.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.3 percentage points.
Neurocrine Biosciences Inc's quarterly ROE was 5.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.4 percentage points.
Capital Allocation
Neurocrine Biosciences Inc invested $351.8M in research and development in Q3 2026. This represents an increase of 40.7% from the same quarter a year earlier. Against the prior quarter it is up 7.7%.
Neurocrine Biosciences Inc spent $92.1M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 667.5%.
Neurocrine Biosciences Inc invested $11.6M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 12.1% from the same quarter a year earlier. Against the prior quarter it is up 48.7%.
NBIX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B+41.2% | $959.0M+39.5% | $814.5M+42.2% | $805.5M+28.3% | $794.9M+27.8% | $687.5M+16.5% | $572.6M+11.1% | $627.7M+21.8% |
| Cost of Revenue | $26.6M+90.0% | $23.2M+105.3% | $13.8M+50.0% | $17.6M+89.2% | $14.0M+75.0% | $11.3M+22.8% | $9.2M+22.7% | $9.3M+9.4% |
| Gross Profit | $1.1B+40.4% | $935.8M+38.4% | $800.7M+42.1% | $787.9M+27.4% | $780.9M+27.2% | $676.2M+16.4% | $563.4M+10.9% | $618.4M+22.0% |
| R&D Expenses | $351.8M+40.7% | $326.7M+33.7% | $296.2M+12.5% | $258.2M+39.1% | $250.0M+28.2% | $244.3M+27.8% | $263.2M+65.1% | $185.6M+35.0% |
| SG&A Expenses | $366.3M+25.6% | $439.7M+53.6% | $318.5M+15.2% | $301.8M+4.9% | $291.6M+24.5% | $286.3M+18.3% | $276.5M+13.7% | $287.8M+31.5% |
| Operating Income | $331.3M+38.6% | $151.5M+4.1% | $193.4M+719.5% | $210.9M+48.5% | $239.0M+30.0% | $145.6M+0.1% | $23.6M-76.2% | $142.0M-5.5% |
| EBITDA | $375.3M+52.1% | $176.3M+15.3% | $200.7M+543.3% | $218.4M+46.5% | $246.7M+29.6% | $152.9M+0.1% | $31.2M-70.4% | $149.1M-4.4% |
| Interest Expense | $300Kn/m | $2.9Mn/m | N/A | N/A | $0 | $0 | N/A | N/A |
| Income Tax | $77.2M-6.2% | $17.8M-65.8% | $48.9M+619.1% | $85.7M+44.0% | $82.3M+36.0% | $52.0M+54.8% | $6.8Mn/m | $59.5M+17.8% |
| Net Income | $206.5M-1.4% | $144.4M+34.3% | $197.9M+2405.1% | $153.7M+49.1% | $209.5M+61.4% | $107.5M+65.4% | $7.9M-81.8% | $103.1M-30.2% |
| EPS (Basic) | $2.03-3.8% | $1.43+31.2% | $1.97+2362.5% | $1.54+49.5% | $2.11+64.8% | $1.09+70.3% | $0.08-81.4% | $1.03-31.8% |
| EPS (Diluted) | $1.96-3.9% | $1.39+31.1% | $1.91+2287.5% | $1.48+48.0% | $2.04+64.5% | $1.06+68.3% | $0.08-81.0% | $1.00-31.5% |
| Diluted Shares (Avg) | 105M+2.6% | 104M+3.2% | 103M+0.9% | N/A | 103M-1.7% | 101M-2.8% | 103M-1.1% | N/A |
NBIX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.6B+31.9% | $5.4B+37.8% | $4.9B+33.0% | $4.6B+24.5% | $4.3B+20.7% | $3.9B+17.7% | $3.7B+6.2% | $3.7B+14.4% |
| Current Assets | $2.0B-7.0% | $1.6B-6.4% | $2.4B+48.7% | $2.5B+46.3% | $2.2B+15.0% | $1.7B+4.7% | $1.6B-9.0% | $1.7B+7.3% |
| Cash & Equivalents | $641.5M+88.6% | $332.4M+25.9% | $266.5M+37.3% | $713.0M+206.0% | $340.2M-2.5% | $264.0M+89.0% | $194.1M-51.0% | $233.0M-7.2% |
| Short-Term Investments | $96.4M-87.6% | $57.4M-91.9% | $1.0B+40.1% | $767.4M-9.0% | $774.6M-11.9% | $711.6M-20.9% | $749.4M-8.0% | $843.1M+8.0% |
| Inventory | $66.1M-4.6% | $104.2M+83.1% | $64.5M+9.1% | $69.0M+20.2% | $69.3M+51.3% | $56.9M+33.9% | $59.1M+58.9% | $57.4M+49.9% |
| Accounts Receivable | $957.3M+31.5% | $887.0M+48.9% | $768.1M+48.9% | $686.8M+43.4% | $728.0M+51.3% | $595.7M+27.2% | $516.0M+14.5% | $479.1M+9.1% |
| Long-Term Investments | $51.8M-94.8% | $91.9M-89.5% | $1.3B+63.3% | $1.1B+43.7% | $998.5M+55.1% | $873.8M+37.0% | $815.3M+16.4% | $739.5M+7.6% |
| Goodwill | $500.6M | $500.6M | $6.0M | $6.1M+7.0% | N/A | N/A | N/A | $5.7M-1.7% |
| Total Liabilities | $1.7B+38.6% | $1.7B+39.3% | $1.5B+30.1% | $1.4B+22.1% | $1.3B+54.7% | $1.2B+50.2% | $1.2B+6.0% | $1.1B+10.8% |
| Current Liabilities | $984.6M+54.3% | $874.5M+60.1% | $831.7M+59.1% | $743.4M+46.4% | $638.0M+48.5% | $546.3M+37.1% | $522.9M-26.7% | $507.7M-22.5% |
| Non-Current Liabilities | $764.1M+22.4% | $791.0M+21.8% | $667.1M+6.0% | $635.0M+2.2% | $624.1M+61.5% | $649.2M+63.4% | $629.1M+68.5% | $621.3M+70.4% |
| Total Equity | $3.9B+29.1% | $3.7B+37.1% | $3.4B+34.4% | $3.3B+25.6% | $3.0B+10.5% | $2.7B+7.4% | $2.5B+6.3% | $2.6B+16.0% |
| Retained Earnings | $838.4M+185.2% | $724.0M+756.8% | $589.6Mn/m | $447.7M+1433.2% | $294.0M+262.5% | $84.5Mn/m | -$5.3Mn/m | $29.2Mn/m |
Not reported in any period shown, so not listed: Long-Term Debt.
NBIX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $395.2M+73.7% | $136.4M+33.7% | $145.8M+125.0% | $388.4M+60.2% | $227.5M+44.0% | $102.0M+57.9% | $64.8M-50.3% | $242.5M+96.4% |
| Depreciation & Amortization | $44.0M+471.4% | $24.8M+239.7% | $7.3M-3.9% | $7.5M+5.6% | $7.7M+18.5% | $7.3M0.0% | $7.6M+22.6% | $7.1M+24.6% |
| Stock-Based Compensation | N/A | N/A | $57.2M+8.3% | N/A | N/A | N/A | $52.8M+18.7% | N/A |
| Capital Expenditures | $11.6M-12.1% | $7.8M-37.6% | $9.1M-15.0% | N/A | $13.2M+63.0% | $12.5M+7.8% | $10.7M-4.5% | $7.3M+35.2% |
| Free Cash Flow | $383.6M+79.0% | $128.6M+43.7% | $136.7M+152.7% | N/A | $214.3M+43.0% | $89.5M+68.9% | $54.1M-54.6% | $235.2M+99.2% |
| Investing Cash Flow | -$11.1Mn/m | -$135.4Mn/m | -$506.2M-3664.8% | -$52.9Mn/m | -$196.7M-896.4% | -$29.0Mn/m | $14.2Mn/m | -$68.3Mn/m |
| Financing Cash Flow | -$75.0M-264.5% | $63.4Mn/m | -$86.1Mn/m | $37.3Mn/m | $45.6M+72.7% | -$3.3Mn/m | -$117.9M-268.7% | -$290.0M-919.2% |
| Share Buybacks | $92.1Mn/m | $12.0M-32.2% | $54.0M-64.0% | $0-100.0% | $0n/m | $17.7Mn/m | $150.0Mn/m | $300.0M |
Not reported in any period shown, so not listed: Dividends Paid.
NBIX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.6%-0.6pp | 97.6%-0.8pp | 98.3%-0.1pp | 97.8%-0.7pp | 98.2%-0.5pp | 98.4%-0.1pp | 98.4%-0.2pp | 98.5%+0.2pp |
| Operating Margin | 29.5%-0.6pp | 15.8%-5.4pp | 23.7%+19.6pp | 26.2%+3.6pp | 30.1%+0.5pp | 21.2%-3.5pp | 4.1%-15.2pp | 22.6%-6.6pp |
| Net Margin | 18.4%-8.0pp | 15.1%-0.6pp | 24.3%+22.9pp | 19.1%+2.6pp | 26.4%+5.5pp | 15.6%+4.6pp | 1.4%-7.0pp | 16.4%-12.2pp |
| Return on Equity | 5.3%-1.7pp | 3.9%-0.1pp | 5.8%+5.5pp | 4.7%+0.7pp | 7.0%+2.2pp | 4.0%+1.4pp | 0.3%-1.5pp | 4.0%-2.6pp |
| Return on Assets | 3.7%-1.2pp | 2.7%-0.1pp | 4.0%+3.8pp | 3.3%+0.6pp | 4.9%+1.2pp | 2.8%+0.8pp | 0.2%-1.0pp | 2.8%-1.8pp |
| Current Ratio | 2.04-1.3x | 1.87-1.3x | 2.93-0.2x | 3.390.0x | 3.38-1.0x | 3.20-1.0x | 3.13+0.6x | 3.40+0.9x |
| Liabilities-to-Equity | 0.450.0x | 0.450.0x | 0.440.0x | 0.420.0x | 0.42+0.1x | 0.44+0.1x | 0.450.0x | 0.440.0x |
| Asset Turnover | 0.200.0x | 0.180.0x | 0.170.0x | 0.170.0x | 0.190.0x | 0.180.0x | 0.160.0x | 0.170.0x |
| FCF Margin | 34.2%+7.2pp | 13.4%+0.4pp | 16.8%+7.3pp | N/A | 27.0%+2.9pp | 13.0%+4.0pp | 9.4%-13.7pp | 37.5%+14.5pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Neurocrine Biosciences Inc NBIX | FY2025 | $2.9B | $478.6M | 16.7% | $16.9B | 79/100 |
| Elanco Animal Health Incorporated ELAN | FY2025 | $4.7B | -$232.0M | -4.9% | $13.4B | 44/100 |
| United Therapeutics Corp UTHR | FY2025 | $3.2B | $1.3B | 41.9% | $25.2B | 88/100 |
| Viatris Inc. VTRS | FY2025 | $14.3B | -$3.5B | -24.6% | $23.9B | 28/100 |
| Dr. Reddy's Laboratories Limited RDY | FY2026 | $3.6B | $456.6M | 12.8% | $12.3B | 72/100 |
| Zoetis Inc. ZTS | FY2025 | $9.5B | $2.7B | 28.2% | $34.1B | 72/100 |
Where Neurocrine Biosciences Inc Ranks
Frequently Asked Questions
Neurocrine Biosciences Inc (NBIX) reported $2.9B in total revenue for fiscal year 2025. This represents a 21.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Neurocrine Biosciences Inc (NBIX) revenue grew by 21.4% year-over-year, from $2.4B to $2.9B in fiscal year 2025.
Yes, Neurocrine Biosciences Inc (NBIX) reported a net income of $478.6M in fiscal year 2025, with a net profit margin of 16.7%.
Neurocrine Biosciences Inc (NBIX) had EBITDA of $649.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Neurocrine Biosciences Inc (NBIX) had a gross margin of 98.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Neurocrine Biosciences Inc (NBIX) had an operating margin of 21.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Neurocrine Biosciences Inc (NBIX) had a net profit margin of 16.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Neurocrine Biosciences Inc (NBIX) has a return on equity of 14.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Neurocrine Biosciences Inc (NBIX) generated $748.7M in free cash flow during fiscal year 2025. This represents a 34.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Neurocrine Biosciences Inc (NBIX) generated $782.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Neurocrine Biosciences Inc (NBIX) had $4.6B in total assets as of fiscal year 2025, including both current and long-term assets.
Neurocrine Biosciences Inc (NBIX) invested $34.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Neurocrine Biosciences Inc (NBIX) invested $1.0B in research and development during fiscal year 2025.
Neurocrine Biosciences Inc (NBIX) had a current ratio of 3.39 as of fiscal year 2025, which is generally considered healthy.
Neurocrine Biosciences Inc (NBIX) had a liabilities-to-equity ratio of 0.42 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Neurocrine Biosciences Inc (NBIX) had a return on assets of 10.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Neurocrine Biosciences Inc (NBIX) trades at 24.1x earnings, its market capitalization divided by $702.5M net income, trailing 12 months to September 30, 2026. The market capitalization is $16.9B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Neurocrine Biosciences Inc (NBIX) trades at 4.6x sales, its market capitalization divided by $3.7B revenue, trailing 12 months to September 30, 2026. The market capitalization is $16.9B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Neurocrine Biosciences Inc (NBIX) has an Altman Z-Score of 9.03, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Neurocrine Biosciences Inc (NBIX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Neurocrine Biosciences Inc (NBIX) has an earnings quality ratio of 1.64x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Neurocrine Biosciences Inc (NBIX) scores 79 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.